5 Papers
42 Citations
Xiaohui Jiang is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Histamine H3 receptor & Histamine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Blockade of Orexin-1 Receptors Attenuates Orexin-2 Receptor Antagonism-Induced Sleep Promotion in the Rat
Christine Dugovic,Jonathan Shelton,Leah Aluisio,Ian Fraser,Xiaohui Jiang,Steven W. Sutton,Pascal Bonaventure,Sujin Yun,Xiaorong Li,Brian Lord,Curt A. Dvorak,Nicholas I. Carruthers,Timothy W. Lovenberg +12 more
TL;DR: Results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.
248
Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors
Kiev S. Ly,Michael A. Letavic,John M. Keith,Jennifer M. Miller,Emily M. Stocking,Ann J. Barbier,Pascal Bonaventure,Brian Lord,Xiaohui Jiang,Jamin D. Boggs,Lisa Dvorak,Kirsten L. Miller,Diane Nepomuceno,Sandy J. Wilson,Nicholas I. Carruthers +14 more
TL;DR: The synthesis and biological activity of a new series of piperazine and diazepane amides is described, which are high affinity histamine H3 ligands and serotonin reuptake inhibitors.
23
Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [11C]GSK189254 in anesthetized baboon
Jean Logan,Nicholas I. Carruthers,Michael A. Letavic,Steven B Sands,Xiaohui Jiang,Colleen Shea,Lisa Muench,Youwen Xu,Pauline Carter,Payton King,Joanna S. Fowler +10 more
TL;DR: The robust blockade of binding of [11C]GSK189254 by JNJ-39220675 demonstrates that this compound readily penetrates the blood–brain barrier and occupies the histamine H3 receptor after oral administration at low plasma concentrations (∼1 ng/cc) supporting further drug development for alcohol addiction and other disorders.
20
Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Emily M. Stocking,Leah Aluisio,John R. Atack,Pascal Bonaventure,Nicholas I. Carruthers,Christine Dugovic,Anita M. Everson,Ian Fraser,Xiaohui Jiang,Perry Leung,Brian Lord,Kiev S. Ly,Kirsten L. Morton,Diane Nepomuceno,Chandravadan R. Shah,Jonathan Shelton,Akinola Soyode-Johnson,Michael A. Letavic +17 more
TL;DR: Pre-clinical characterization of novel substituted pyrrolidines that are high affinity histamine H(3) receptor antagonists is described and one compound, (2S,4R)-1-[2-(4-cyclobutyl-[1,4]diazepane-1-carbonyl)-4-(3-fluoro-phenoxy)-p Pyrrolidin-1,yl]-ethanone, shows promise as a potential clinical candidate.
4
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development.
Michael A. Letavic,Leah Aluisio,John R. Atack,Pascal Bonaventure,Nicholas I. Carruthers,Christine Dugovic,Anita M. Everson,Mark A. Feinstein,Ian Fraser,Kenway Hoey,Xiaohui Jiang,John M. Keith,Tatiana Koudriakova,Perry Leung,Brian Lord,Timothy W. Lovenberg,Kiev S. Ly,Kirsten L. Morton,S. Timothy Motley,Diane Nepomuceno,Michele C. Rizzolio,Raymond Rynberg,Kia Sepassi,Jonathan Shelton +23 more
TL;DR: The pre-clinical characterization of novel aryloxypyridine amides that are histamine H(3) receptor antagonists is described, leading to the identification of two compounds suitable for nomination as development candidates.